Skip to main content

Bio-Rad Q3 Revenues Rise 8 Percent as Profit Surges 43 Percent

NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said third-quarter revenues increased 8 percent as R&D spending rose 8 percent and profit increased 43 percent.
Total receipts for the three months ended Sept. 30 increased to $305 million from $283 million year over year.
Revenue from the company’s Life Science division was up 4 percent to $137 million from $132 million while receipts from the Clinical Diagnostics segment jumped 11 percent to $164 million from $148 million year over year.
Bio-Rad said increased sales in Life Science came from first orders of its new Protein Array Interaction System, and the growth in its Clinical Diagnostics was “across all product lines.”
R&D spending increased to $31 million from $29 million year over year.
The company said third-quarter profit increased to $23.1 million from $16.2 million in the year-ago period.
Bio-Rad said it had around $481.5 million in cash, cash equivalents, and short-term investments as of Sept. 30.
Yesterday, GenomeWeb News reported that Bio-Rad’s impending acquisition of Ciphergen’s proteomics tool business has been delayed. In a statement, Bio-Rad said the acquisition "is in the process of being completed."

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.